Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LXR-623 · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| LXR-623 | DRUG | - |
Inclusion: * Healthy, men or women, aged 19-50 years Exlcusion: * Use of any investigational or prescription drug within 30 days before study start * Any clinically imprtant medical disease or abnormal laboratory test results
LXR-623 is an investigational small molecule developed by Pfizer, Inc. (ticker PFE). It is a liver X receptor agonist that has been studied in Phase 1 clinical trials in healthy volunteers. No approved indication has been disclosed for LXR-623.
LXR-623 targets NR1H3 and NR1H2, also known as liver X receptor alpha and beta. It acts as an agonist at these nuclear receptors. By activating NR1H3 and NR1H2, LXR-623 modulates gene expression related to lipid metabolism and cholesterol homeostasis.
LXR-623 is developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer is the sponsor of the clinical trials evaluating LXR-623.
LXR-623 is in Phase 1 clinical development. It has completed two Phase 1 trials but is not approved for any indication. The trials were conducted in healthy volunteers to evaluate the drug's safety and tolerability.
LXR-623 has been evaluated in two completed Phase 1 trials: NCT00385489, which studied the drug in healthy Japanese adults in Japan, and NCT00366522, which studied healthy subjects in the United States. Both trials are completed and no active trials are ongoing.